Clinical trials: Early Memory Loss, active
Alzheimer Disease, Mild Cognitive Impairment
Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants
Phase 1b study to assess the pharmacodynamics, safety, tolerability, and pharmacokinetics of NIO752 in patients with early Alzheimer's disease (AD)
- Trial name
- NCT05469360
- Testing
- NIO752
- Where
- 10 sites in Finland, France and 2 more
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Alzheimer Disease, Hearing Loss
Early Age-Related Hearing Loss Investigation (EARHLI)
Early Age-Related Hearing Loss Investigation (EARHLI) is a single site study that will randomize late middle age adults to either a hearing intervention (including hearing aids) or a health education intervention.
- Conditions
- Alzheimer Disease, Hearing Loss, Cognitive Impairment
- Trial name
- EARHLI (NCT06174038)
- Testing
- Hearing Intervention, Health Education Intervention
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Columbia University
Dementia, Early Onset, Alzheimer Dementia (AD)
Genetic Studies of Early-onset Dementia
The aim of this study is to identify genetic factors that contribute to risk and progression of early-onset dementia (loss of memory function before the age of 70 years) across all ethnic groups, including Alzheimer's Disease…
- Conditions
- Dementia, Early Onset, Alzheimer Dementia (AD), Mild Cognitive Impairment (MCI), Memory Loss
- Trial name
- NCT04906863
- Testing
- Blood draw, Neurocognitive testing, Medical questionnaire
- Where
- United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Columbia University
Alzheimer Disease
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)
The primary purpose of this study is to evaluate the efficacy of sabirnetug infusions administered once every four weeks (Q4W) in slowing cognitive and functional decline as compared to placebo in participants with early…
- Trial name
- ALTITUDE-AD (NCT06335173)
- Testing
- sabirnetug
- Where
- 68 sites in United States, Canada and 3 more
- Volunteers
- 542 people
- Sponsor
- Acumen Pharmaceuticals
Rare Disorders, Undiagnosed Disorders
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Coordination of Rare Diseases at Sanford (CoRDS) is an international patient registry that serves as a centralized resource for rare disease research.
- Conditions
- Rare Disorders, Undiagnosed Disorders, Disorders of Unknown Prevalence, Cornelia De Lange Syndrome
- Trial name
- CoRDS (NCT01793168)
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- Sanford Health
Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease
NON-INVASIVE BRAIN STIMULATION FOR MEMORY LOSS IN EARLY ALZHEIMER'S DISEASE
The goal of this clinical trial is to learn if repetitive transcranial magnetic stimulation (rTMS), a non-invasive form of brain stimulation, can improve short-term memory in people with early Alzheimer's disease (AD).
- Conditions
- Alzheimer s Disease, Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease, Mild Dementia
- Trial name
- NCT07667478
- Testing
- repetitive transcranial magnetic stimulation (rTMS)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Chi-Ying (Roy) Lin
Cognitive Disorder, Deafness
EARLY DETECTION OF DEAFNESS IN A MEMORY CENTER
Age-related hearing loss (ARHL), like neurodegenerative diseases, appears insidiously with age. As major public health issues, they are nonetheless under-diagnosed because the presence of one can hinder the objectification of the…
- Trial name
- CogAudio (NCT06088953)
- Testing
- VRB test
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Lille
Mild Cognitive Impairment, Alzheimer's Disease
Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia
Bio-Hermes-002 is a 120-day cross-sectional study that will result in a blood, CSF, retinal, digital, MRI, and PET brain imaging biomarker database that can be used to determine the primary objective.
- Conditions
- Mild Cognitive Impairment, Alzheimer's Disease, Alzheimer's Disease, Early Onset, Memory Loss
- Trial name
- Bio-Hermes-002 (NCT06584357)
- Testing
- Biomarker Data Collection, MK6240
- Where
- 26 sites in United States, Canada and 1 more
- Volunteers
- 1,200 people, healthy volunteers welcome
- Sponsor
- GAP Innovations, PBC